Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- M&A Inevitable for Japanese Drug Companies: Nikko Solomon's Analyst
September 24, 2001
- FY2001 Korosho White Paper Stresses Importance of Social Security as Safety Net
September 24, 2001
- 9 Active Ingredients to Be Approved in September
September 24, 2001
- PMSB to Take Measures to Ensure Quality of Imported Medical Devices
September 24, 2001
- REGULATORY NEWS IN BRIEF
September 24, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
September 24, 2001
- Taisho, Tanabe Agree to Integrate Their Business
September 24, 2001
- GEYMS Launches New Multislice CT "LightSpeed Ultra" in Japan First
September 24, 2001
- DIAGNOSTIC NEWS IN BRIEF
September 24, 2001
- Terumo Takes Over Home Oxygen Business from Sumitomo Bakelite
September 24, 2001
- Sankyo to Give Greater Importance to Clinic Market for Life-style Diseases
September 24, 2001
- Takara Launches Nexell's Magnetic Cell Separation System from Nexell
September 24, 2001
- 51% of JPMA Member Firms Have Documented Compliance Programs
September 24, 2001
- Makers Outsource More OTC Drug Marketing Activities
September 24, 2001
- FJPWA Decides to Cooperate in Market Price Survey
September 24, 2001
- OTC NEWS IN BRIEF
September 24, 2001
- Wholesalers' Bargaining Ability to Be Tested in 2002
September 24, 2001
- WORLD NEWS IN BRIEF
September 24, 2001
- BUSINESS NEWS IN BRIEF -1-
September 24, 2001
- P450 DB Provides Valuable Information on Drug Interactions: FQS, Shionogi
September 24, 2001
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…